Verrica Pharmaceuticals
2013
FOUNDED
PUBLIC
STATUS
11-20
EMPLOYEES
VRCA
STOCK SYMBOL
$13.79
SHARE PRICE
(As of Friday Closing)
Description
Developer of a biopharmaceutical platform designed to develop innovative therapies for common skin diseases. The company's platform focuses on identifying, developing and commercializing innovative therapies to unmet needs in medical dermatology thereby helping patients to have less pain and time-consuming treatment, enabling dermatologists to better administer cantharidin for warts and skin diseases.
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Primary Office
- Durham, NC
- United States
+1 (610) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Verrica Pharmaceuticals’s full profile, request a free trial.
Verrica Pharmaceuticals Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $13.21 - $20.34 | $355M | $13.81 | -$1.81 | 73.7K | 25.7M |
Verrica Pharmaceuticals Financials Summary
|
In Thousands,
USD |
TTM
30-Jun-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
FY 2015
31-Dec-2015
|
|---|---|---|---|---|
| Enterprise Value | 464,707 | |||
| Revenue | 0 | 0 | ||
| EBITDA | (10,819) | (4,457) | (1,913) | |
| Net Income | (10,627) | (4,459) | (1,913) | (1,913) |
| Total Assets | 104,716 | 9,083 | 544 | |
| Total Debt | 0 | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Verrica Pharmaceuticals Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Verrica Pharmaceuticals‘s full profile, request access.
Request full access to PitchBookVerrica Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is reserved for PitchBook Platform users. To explore Verrica Pharmaceuticals‘s full profile, request access.
Request full access to PitchBookVerrica Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Verrica Pharmaceuticals‘s full profile, request access.
Request full access to PitchBookVerrica Pharmaceuticals Executive Team (6)
1 Former Executive
You’re viewing 5 of 6 executives. Get the full list »Verrica Pharmaceuticals Board Members (5)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Glenn Oclassen | Verrica Pharmaceuticals | Board Member & Advisor | 000 0000 | |
| Jayson Rieger Ph.D | Verrica Pharmaceuticals | Chief Operating Officer & Board Member | 000 0000 | |
| Matthew Davidson Ph.D | Verrica Pharmaceuticals | Founder, Chief Scientific Officer & Board Member | 000 0000 | |
| Paul Manning | PBM Capital Group | Board Member | 000 0000 | |
| Sean Stalfort | Verrica Pharmaceuticals | Board Member | 000 0000 |